Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders aged from 1 month up to less than 18 years at the time of enrolment~* Patients affected by any hereditary haemoglobinopathy requiring chronic transfusion therapy and chelation, including but not limited to thalassemia syndromes and sickle cell disease~* Patients on current treatment with deferoxamine (DFO) or DFX or DFP in a chronic transfusion program receiving at least 150 mL/kg/year of packed red blood cells (corresponding approximately to 12 transfusions);~* For patients naïve to chelation treatment: patients that have received at least 150 mL/kg of packed red blood cells (corresponding to approximately 12 transfusions) in a chronic transfusion program and with serum ferritin levels ≥ 800 ng/mL;~* Until availability of results from the PK Study (Study DEEP-1, EudraCT n. 2012-000658-67) for patients aged from 1 month to less than 6 years: known intolerance or contraindication to DFO;~* Written informed consent and patient's informed assent, relating to his/her comprehension abilities and level of maturity~Exclusion Criteria:~* Patients with intolerance or known contraindication to either DFP or DFX~* Patients receiving DFX at a dose \> 40 mg/kg/day or DFP at a dose \> 100 mg/kg/day at screening~* Platelet count \<100.000/mm3 during the run-in phase~* Absolute neutrophils count \<1.500/mm3 during the run-in phase~* Hb levels lower than 8g/dL during the run-in phase~* Evidence of abnormal liver function~* Iron overload from causes other than transfusional haemosiderosis~* Severe heart dysfunction secondary to iron overload~* Serum creatinine level \> ULN (Upper Limit of Normal) for age during the run-in phase~* History of significant medical or psychiatric disorder~* The patient has received another investigational drug within 30 days prior to this clinical trial~* Fever and other signs/symptoms of infection in the 10 days before baseline assessment~* Concomitant use of trivalent cation-dependent medicinal products such as aluminium-based antacids~* Positive test for β-HCG (Human chorionic gonadotropin) and lactating female patients

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Deferiprone (Type: EXPERIMENTAL): 75-100 mg/kg/day seven days per week
- Deferasirox (Type: ACTIVE_COMPARATOR): 20 to 40 mg/kg/day seven days per week

Based on this trial design, predict the completion outcome and termination type (if applicable).